Abstract
This chapter presents an overview of the background history of diabetic nephropathy. The discovery of diabetic renal disease was a gradual process and the definition of diabetic nephropathy has changed over time. Initial studies of renal biopsies, radioimmunoassay, and the concept of micro- and macroalbuminuria are highlighted, as well as the discovery of renin–angiotensin–aldosterone system (RAAS). Landmark trials focusing on how diabetic nephropathy could be improved using pharmacologic blockade of RAAS are reviewed. Diabetes is the most common cause of end-stage renal disease in Western countries, and trials that highlight the benefit of treating hyperglycemia are presented.
Keywords
- Diabetic Nephropathy
- Glomerular Lesion
- Overt Nephropathy
- Intensive Glycemic Control
- Diabetic Renal Disease
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Krall LP, Levine R, Barnett D. The history of diabetes. In: Kahn CR, Weir GC, editors. Joslin’s diabetes mellitus. Philadelphia: Lea & Febiger; 1994.
Aretaeus, De causis et signis acutorum morborum (lib. 2) Francis Adams LL.D., Ed.
Stewart Cameron J. The discovery of diabetic nephropathy: from small print to centre stage. J Nephrol. 2006;10:S75.
Darwin E. Zoonomia (The Laws of Organic Life). 1801.
Cotunnius D. De Ischiade Nervosa. Vienna, 1770.
Rollo J. Cases of the diabetes mellitus. 2nd ed. London: Dilly; 1798.
Cameron JS, Ireland JT, Watkins PJ. The kidney and renal tract. In: Keen HF, Jarrett J, editors. Complications of diabetes. London: Edward Arnold Ltd.; 1975. p. 99.
Rayer P. In: Traite des Maladies du Rein, Vol. 2. Baillere, Tindall, and. Cox, editors. Paris; 1840.
Griesinger W. Studien uber diabetes. Archiv Physiologie Heilkunde. 1859;3:1–75.
Ebstein W. Weiteres über Diabetes mellitus, insbesondere über die Complicationdesselben mit Typhus abdominalis. Deutsch Arch f klin Med 1882;30:1–44.
Waku K. Ueber die Verunderung der Glomeruli der Diabetesniere. Tr Jap Path Soc. 1928;18:413–6.
Kimmelstiel P, Wilson C. Intercapillary lesions in glomeruli of kidney. Am J Pathol. 1936;12:83.
Allen AC. So-called intercapillary glomerulosclerois—a lesion associated with diabetes. Arch Pathol. 1941;32:33–51.
Iversen P, Brun C. Aspiration biopsy of the kidney. Am J Med. 1951;11(3):324–30.
Gellman DD, Pirani CL, Soothill JF, Muehrcke RC, Kark RM. Diabetic nephropathy. A clinical and pathologic study based on renal biopsies. Medicine (Baltimore). 1959;38:321–67.
Irvine E, Rinehart JF, Mortimore GE, Hopper JJ. The ultrastructure of the renal glomerulus in intercapillary glomerulosclerosis. Am J Pathol. 1956;32:647–53.
Østerby-Hansen R. A quantitative estimate of the peripheral glomerular basement membrane in recent juvenile diabetes. Diabetologia. 1965;1:97–100.
Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960;39:1157–75.
Keen H, Chlouverakis C. An immunoassay method for urinary albumin in low concentrations. Lancet. 1963;ii:913–6.
Viberti GC, Hill RD, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetics. Lancet. 1982;i:1430–2.
Mogensen DE. Microabluminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–60.
Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J. 1982;285:685–8.
American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:S65–7.
Basso N, Terragno NA. History about the discovery of the renin-angiotensin system. Hypertension. 2001;38:1246–9.
Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T. Declining incidence of persistent proteinuria in type I (insulin-dependent) diabetics. Diabetes. 1987;36:205–9.
Krolewski AS, Warram JH, Chriestleib AR, Busick EJ, Kathan CR. The changing natural history of nephropathy in type I diabetes. Am J Med. 1985;78:785–94.
Zatz R, Brenner BM. Pathogenesis of diabetic nephropathy. The hemodynamic view. Am J Med. 1985;80:443–53.
Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J. 1988;297:1092–5.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–62.
Lewis EJ, Hunsicker LG, Clarke WR, et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.
Brenner BM, Cooper ME, de Zeeuw D, et al., for the RENAAL Study Investigators. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–69.
Barnett AH. Inhibition of the renin-angiotensin system in diabetic patients—beyond HOPE. Br J Cardiol. 2004;11:123–7.
Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. Brenner and rector’s the kidney. 7th ed. Philadelphia: WB Saunders; 2004. p. 1777–818.
The EURODIAB IDDM Complications Study Group. Microvascular and acute complications in insulin dependent diabetes mellitus: The EURODIAB IDDM Complications Study. Diabetologia. 1994;37:278–85.
Steffes MW, Sutherland DER, Goetz FC, Rich SS, Mauer SM. Studies of kidney and muscle biopsy specimens from identical twins discordant for type I diabetes mellitus. N Engl J Med. 1985;312:1282–7.
Mauer SM, Goetz FC, McHugh LE, Sutherland DE, Barbosa J, Najarian JS, Steffes MW. Long-term study of normal kidneys transplanted into patients with type I diabetes. Diabetes. 1989;38:516–23.
Mauer SM, Steffes MW, Connett J, Najarian JS, Sutherland DE, Barbosa J. The development of lesions in the glomerular basement membrane and mesangium after transplantation of normal kidneys into diabetic patients. Diabetes. 1983;32:948–52.
Wiseman AC. Pancreas transplant options for patients with type 1 diabetes mellitus and chronic kidney disease: simultaneous pancreas kidney or pancreas after kidney? Curr Opin Organ Transplant. 2012;17(1):80–6.
Bohman S-O, Tyden G, Wilczek H, Lundgren G, Jaremko G, Gunnarsson R, Ostman J, Groth G. Prevention of kidney graft diabetic nephropathy by pancreas transplantation in man. Diabetes. 1985;34:306–8.
Wilczek HE, Jaremko G, Tyden G, Groth CG. Pancreatic graft protects a simultaneously transplanted kidney from developing diabetic nephropathy: a 1 to 6 year follow-up study. Transplant Proc. 1993;1:1314–5.
Young BY, Gill J, Huang E, et al. Living donor kidney versus simultaneous pancreas-kidney transplant in type I diabetics: an analysis of the OPTN/UNOS database. Clin J Am Soc Nephrol. 2009;4:845–52.
European Association for the Study of Diabetes (EASD) 48th Annual Meeting: Abstract 149. Presented October 4, 2012.
Diabetes Complications and Control Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–53.
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.
Levin SR, Coburn JW, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care. 2000;23(10):1478–85.
Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22(1):99–111.
Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus systematic review and meta-analysis. Arch Intern Med. 2012;172(10):761–9.
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in diabetes study group. type 2 diabetes. N Engl J Med. 2008;358:2545–59.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care. 2010;33(1):73–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Haggar, M., Fonseca, V. (2014). The Background History of Diabetic Nephropathy. In: Lerma, E., Batuman, V. (eds) Diabetes and Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0793-9_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0793-9_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0792-2
Online ISBN: 978-1-4939-0793-9
eBook Packages: MedicineMedicine (R0)